Article
Gastroenterology & Hepatology
Alessandro Mannucci, Ferdinando D'Amico, Ahmad El Saadi, Laurent Peyrin-Biroulet, Silvio Danese
Summary: Filgotinib has demonstrated remarkable efficacy, safety, and tolerability in the treatment of moderate-to-severe active UC. It can be used in both biologic-naive and biologic-experienced patients. The rapid mechanism of action and oral administration route make it a reliable therapeutic option.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Edward V. Loftus, Severine Vermeire, Brian G. Feagan, Franck-Olivier Le Brun, Alessandra Oortwijn, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi
Summary: In patients with ulcerative colitis, the study found that 200 mg of filgotinib can reduce the use of corticosteroids and maintain corticosteroid-free clinical remission. Moreover, compared to other medications, filgotinib demonstrated better outcomes in patients who had not previously used biologic agents.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
David T. Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham Radford-Smith, Peter D. R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young S. Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, Julian Panes
Summary: Etrolizumab showed superiority over placebo in inducing remission in HIBISCUS I, but not in HIBISCUS II. Etrolizumab was well tolerated in both studies.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Xiaoyan Lu, Zheng-Yi Zhou, Yiqiao Xin, Min-Jung Wang, Emma Gray, Vipul Jairath, James Oliver Lindsay
Summary: Matching-adjusted indirect comparisons suggest that filgotinib has similar efficacy, safety, and health-related quality of life outcomes compared to vedolizumab, tofacitinib, and ustekinumab in patients with ulcerative colitis. Filgotinib shows improved clinical response and corticosteroid-free clinical remission in certain patient populations, making it a potential advanced therapy option for moderately to severely active UC.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
William Yuan, Jayson S. Marwaha, Shana T. Rakowsky, Nathan P. Palmer, Isaac S. Kohane, David T. Rubin, Gabriel A. Brat, Joseph D. Feuerstein
Summary: Population-scale analysis reveals patterns in prescribing trends for ulcerative colitis management, including earlier use of biologics, associations of step-up therapy with higher corticosteroid exposure, and association of combination therapy with positive patient outcomes.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Severine Vermeire, Peter L. Lakatos, Timothy Ritter, Stephen Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Kadva, Helen Tyrrell, Young S. Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Christopher Eden, Wenhui Zhang, Brian G. Feagan
Summary: This study evaluated the efficacy and safety of etrolizumab for maintenance of remission in patients with moderately to severely active ulcerative colitis. The results showed no significant differences between maintenance etrolizumab and placebo in achieving remission at week 62 among patients with a clinical response at week 10. Etrolizumab was well tolerated in this population, with no new safety signals identified.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Microbiology
Lingyun Xu, Yingchao Li, Yingli He
Summary: Anxiety and depression still exist in UC patients even in the remission period. This study found that the composition of intestinal microbiota differs between UC patients with anxiety and depression and those without, with a decrease in probiotics and an increase in pathogens in the former group. These findings may provide new insights into the recurrence of UC caused by impaired psychological function and offer potential treatment strategies for UC patients with psychological issues.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. R. Higgins, Edward V. Loftus Jr, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hebuterne, James O. Lindsay, Qian Cao, Hiroshi Nakase, Jean-Frederic Colombel, Severine Vermeire
Summary: Upadacitinib demonstrates efficacy and safety for 16-week induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy may benefit from an additional 8 weeks of therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Anthony Otley, Yuri Sanchez Gonzalez, Kristina Fitzgerald, Wen Zhou, Dapo Ilo, Triza Brion, Muna J. J. Tahir
Summary: Due to the wide-ranging impacts of Ulcerative Colitis (UC), the development and validation of the Ulcerative Colitis-Symptom Questionnaire (UC-SQ) was described. The UC-SQ showed evidence of reliability, validity, and responsiveness, making it a suitable tool for use in pivotal UC trials.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Medicine, General & Internal
Xiaochen Zhang, Dai Ishikawa, Kei Nomura, Naoyuki Fukuda, Mayuko Haraikawa, Keiichi Haga, Tomoyoshi Shibuya, Toshihiro Mita, Akihito Nagahara
Summary: Fecal microbiota transplantation is considered a promising treatment for dysbiosis-related diseases. The authors report their experience with donor screening and provide references to improve future donor screening criteria.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
William J. Sandborn, Brian G. Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J. Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C. Wolf, Geert D'Haens
Summary: The study examined the long-term safety and efficacy of Ozanimod in patients with moderately to severely active ulcerative colitis, showing continued benefits in clinical response, endoscopic improvement, and biomarker measures with 1 mg daily dosage. The high rate of study participation and long-term benefit indicates the potential of Ozanimod as a treatment option for UC patients.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Jiaqi Yao, Ginenus Fekadu, Siew C. Ng, Joyce H. S. You
Summary: Based on the study, standard treatment plus FMT therapy appears to be more effective than standard therapy alone for patients with mild-to-moderate active UC. The cost-effectiveness of this treatment is highly dependent on the relative improvement in achieving remission with standard therapy plus FMT therapy and the number of FMT administrations per FMT course.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Immunology
Qiongyun Chen, Yanyun Fan, Bangzhou Zhang, Changsheng Yan, Zhangran Chen, Lin Wang, Yiqun Hu, Qingwen Huang, Jingling Su, Jianlin Ren, Hongzhi Xu
Summary: This study examined the association between gut fungal community and capsulized FMT outcomes in ulcerative colitis (UC) patients. The results showed that capsulized FMT improved fungal diversity and induced remission in UC patients. Specific fungal species were identified to be associated with the induction of remission. This study provides important insights into the mechanism of FMT treatment for UC.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Essi K. Karjalainen, Laura Renkonen-Sinisalo, Reetta Satokari, Harri Mustonen, Ari Ristimaki, Perttu Arkkila, Anna H. Lepisto
Summary: The fecal microbiota transplantation treatment did not show efficacy in treating chronic pouchitis, however the safety profile was good. Among patients who were using continuous antibiotics before the study, the relapse-free survival was shorter in the intervention group.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
Silvio Danese, Remo Panaccione, Maria T. Abreu, David T. Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C. Wolf, Michael Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T. Osterman, Hsiuanlin Wu, James B. Canavan, Annkatrin Petersen, Jean-Frederic Colombel, Miguel Regueiro
Summary: This interim analysis examines the efficacy and safety of ozanimod treatment in patients with ulcerative colitis over a period of approximately 3 years. The results show that a high percentage of patients maintain clinical and mucosal efficacy during the treatment. No new safety concerns arise from long-term use of ozanimod.
JOURNAL OF CROHNS & COLITIS
(2023)